CONTENTS

MINIREVIEW
Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. Zahir Hussain, Junjie Zhu, and Xiaochao Ma ............................................................... 679

ARTICLES
Investigation into MAO B–Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B. April Bai, Veerabahu Shammugasundaram, Julie V. Selkirk, Sekhar Surapaneni, and Deepak Dalvie .......................................................... 601

Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes. Eman El-Khateeb, Zubida M. Al-Majdoub, Amin Rostami-Hodjegan, Jill Barber, and Brahia Machour ................................................................. 610

Pharmacokinetics, Disposition, and Biotransformation of [14C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose. Ashit Trivedi, Jan Wahlstrom, Mia Mackowski, Sandeep Dutta, and Edward Lee .............................................................. 619

BCRP/ABCG2 Transporter Regulates Accumulation of Cadmium in Kidney Cells: Role of the Q141K Variant in Modulating Nephrotoxicity. Xia Wen, Danielle Kozlosky, Ranran Zhang, Catheleen Doherty, Brian Buckley, Emily Barrett, and Lauren M. Aleksunes ......................................................... 629

Characterization of a Novel CYP1A2 Knockout Rat Model Constructed by CRISPR/Cas9. Dongyi Sun, Jian Lu, Yuanjin Zhang, Jie Liu, Zongjian Liu, Bingyi Yao, Yuanqing Guo, and Xin Wang ........................................... 638

Passive Influx and Ion Trapping Are More Relevant to the Cellular Accumulation of Highly Permeable Low-Molecular-Weight Acidic Drugs than Is Organic Anion Transporter 2. Dallas Bednarczyk ......................................................... 648

Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins. Anne M. Filppula, Päivi Hirvensalo, Heli Parviainen, Vilma E. Ivaska, K. Ivar Lönnerg, Feng Deng, Jenni Väänäkki, Mika Kurkela, Mikko Neuvonen, and Mikko Niemi ................................................................. 658

Deconvolution of Cytochrome P450 Induction Mechanisms in HepaRG Nuclear Hormone Receptor Knockout Cells. Lena C. Preiss, Ruoqi Liu, Philip Hewitt, David Thompson, Katrin Georgi, Lassina Badolo, Volker M. Lauschk, and Carl Petersson .......................................................... 668


3,3′-Diindolylmethane Exhibits Significant Metabolism after Oral Dosing in Humans. Monica L. Verrilllon Maier, Lisbeth K. Siddens, Sandra L. Uesugi, Jaewoo Choi, Scott W. Leonard, Jamie M. Pennington, Susan C. Tilton, Jordan N. Smith, Emily Ho,H.H. Sherry Chow, Bach D. Nguyen, Siva K. Kolluri, and David E. Williams ................................................................. 694


Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Docking of ozanimod metabolite RP101075 and its enantiomer (RP101074) in MAO B active site. See the article by Bai et al. (dx.doi.org/10.1124/dmd.121.000447).